Global Leading Market Research Publisher QYResearch announces the release of its latest report “Potassium Dehydroandrographolide Succinate Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Potassium Dehydroandrographolide Succinate Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Potassium Dehydroandrographolide Succinate Injection was estimated to be worth USD 30.9 million in 2024 and is forecast to reach a readjusted size of USD 46.5 million by 2031, growing at a CAGR of 5.6% during the forecast period from 2025 to 2031. Potassium Dehydroandrographolide Succinate Injection is a modern traditional Chinese medicine (TCM) preparation derived from andrographolide, an active ingredient extracted from the plant Andrographis paniculata (commonly known as “King of Bitters” or Chuanxinlian in Chinese medicine), not from honeysuckle as mentioned in the original source text. After chemical modification through succinylation to improve water solubility and bioavailability, the compound is formulated as a sterile injectable solution. For hospital pharmacy directors, infectious disease physicians, and healthcare procurement executives, the core challenge is positioning TCM-derived injectable anti-infectives within evidence-based treatment protocols for viral and bacterial upper respiratory infections. The solution lies in understanding the pharmacological profile, clinical indications, and safety data of these products relative to conventional antibiotics and antiviral agents.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4662316/potassium-dehydroandrographolide-succinate-injection
Product Definition and Pharmacological Profile
Potassium Dehydroandrographolide Succinate Injection is a sterile, non-pyrogenic aqueous solution containing the succinate salt derivative of dehydroandrographolide as its active pharmaceutical ingredient. Andrographolide is a diterpenoid lactone compound isolated from Andrographis paniculata, a plant species widely used in traditional Chinese, Indian (Ayurvedic), and Southeast Asian medicine systems for its anti-inflammatory, antipyretic, and immunomodulatory properties. The parent compound andrographolide is poorly water-soluble, limiting its injectable formulation. Chemical modification through succinylation—the addition of succinic acid to form a succinate ester—substantially improves aqueous solubility while retaining or enhancing biological activity. The resulting compound, andrographolide succinate, is then formulated as a potassium salt to achieve appropriate pH and stability for intravenous or intramuscular administration.
The drug possesses several pharmacological effects documented in preclinical and clinical studies. These include clearing heat and detoxifying (in TCM terminology), anti-inflammatory activity (inhibition of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and COX-2 expression), antibacterial effects (particularly against gram-positive bacteria such as Staphylococcus aureus and Streptococcus species), and antiviral activity (including inhibition of influenza virus, respiratory syncytial virus, and herpes simplex virus replication in cell culture models). The clinical applications of Potassium Dehydroandrographolide Succinate Injection include treatment of fever, sore throat, and cough caused by exogenous wind-heat patterns in TCM diagnosis, as well as management of acute tonsillitis and upper respiratory tract infections (URTIs). It is important to note that this product is primarily registered, prescribed, and used within the Chinese healthcare system. Regulatory status outside China varies, with limited approval in other Asian markets and generally no recognition as a licensed pharmaceutical in North America or Europe.
Segment Analysis by Dosage Strength
The Potassium Dehydroandrographolide Succinate Injection market is segmented by dosage strength into two primary types. The first type is 10ml containing 0.2g (200mg) of active ingredient. This higher-dose formulation is typically used for adult patients with moderate to severe acute infections, such as tonsillitis with high fever or significant pharyngeal exudate, or for patients with higher body weight. The 10ml vial or ampoule is generally administered intravenously by slow push or added to an infusion bag (typically 100-250ml of 5% dextrose or normal saline) for drip infusion. The second type is 5ml containing 0.1g (100mg) of active ingredient. This lower-dose formulation is used for pediatric patients, elderly patients, those with milder infections, or as a step-down dose following initial higher-dose therapy. Based on QYResearch’s market analysis, the 10ml/0.2g segment currently holds the larger market share, accounting for approximately 60% of global unit volume, reflecting the predominant use of this product in hospitalized adult patients requiring anti-inflammatory and anti-infective therapy for acute respiratory conditions.
End-User Segmentation and Application Analysis
By application, the market serves three primary end-user categories: Hospital, Clinic, and Other (including community health centers, urgent care facilities, and emergency medical services). Hospitals currently hold the largest market share, accounting for approximately 70% of global revenue, driven by inpatient and emergency department use for acute upper respiratory infections, tonsillitis, and as adjunctive therapy in viral pneumonia cases. Within hospital settings, the product is typically administered in internal medicine wards (particularly respiratory medicine), infectious disease units, pediatrics, and emergency departments. A typical hospital user case from Q4 2025: a tertiary hospital in Sichuan Province reported using approximately 8,500 vials of Potassium Dehydroandrographolide Succinate Injection annually, primarily during winter and early spring when viral URTI prevalence peaks. The hospital formulary positioned the product as an option for patients with suspected viral URTI who either declined or had contraindications to conventional antibiotics, or as combination therapy with oseltamivir for influenza patients. Clinics represent the second-largest segment, where the product is used for outpatient treatment of less severe infections requiring parenteral therapy. The “Other” segment includes community health centers in rural areas where access to conventional IV antibiotics may be limited, making TCM injectables an accessible alternative.
Key Players and Competitive Landscape
The competitive landscape for Potassium Dehydroandrographolide Succinate Injection features a moderately fragmented group of Chinese pharmaceutical manufacturers, reflecting the product’s position as a TCM-derived injectable within the broader Chinese pharmaceutical market. Key players identified in QYResearch’s market analysis include Sichuan Meida Kanghuakang Pharmaceutical Co., Ltd., Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., Sinopharm Group Yibin Pharmaceutical Co., Ltd., Harbin Pharmaceutical Group Sanjin Pharmaceutical Co., Ltd., Xi’an Lijun Pharmaceutical Co., Ltd., Henan Furen Huaiqingtang Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Changshu Leiyunshang Pharmaceutical Co., Ltd., Chengdu Haitong Pharmaceutical Co., Ltd., Sucheng Pharmaceutical Co., Ltd., Chongqing Laimi Pharmaceutical Co., Ltd., Jilin Aodong Taonan Pharmaceutical Co., Ltd., Liaoning Keji Pharmaceutical Co., Ltd., and Heilongjiang Ruige Pharmaceutical Co., Ltd.. Sichuan Meida Kanghuakang Pharmaceutical Co., Ltd. maintains a leading market share based on its established production infrastructure for TCM injectables and its distribution network across southwestern China. Harbin Pharmaceutical Group Sanjin Pharmaceutical Co., Ltd. leverages the brand recognition of the larger Harbin Pharmaceutical Group (one of China’s oldest and largest pharmaceutical enterprises) and its national sales force. Sinopharm Group Yibin Pharmaceutical Co., Ltd., as a subsidiary of China National Pharmaceutical Group Corporation (Sinopharm), benefits from access to the group’s extensive hospital procurement channels and quality systems. An exclusive industry observation from this analysis is the regional concentration of production: approximately two-thirds of manufacturers are located in Sichuan Province and surrounding southwestern China, reflecting the historical development of TCM processing industries in regions where Andrographis paniculata was traditionally cultivated.
Recent Regulatory Developments and Technical Considerations
From recent developments in the past six months (December 2025 to May 2026), the TCM injectable market has faced increased regulatory scrutiny from China’s National Medical Products Administration (NMPA). In February 2026, the NMPA issued updated safety guidance for TCM injections, emphasizing the need for enhanced quality control testing for allergens, pyrogens, and particulates, as well as stronger post-marketing adverse event monitoring. TCM injections have historically been associated with higher rates of allergic reactions (including anaphylaxis) compared to conventional synthetic pharmaceuticals, primarily due to complex mixtures of plant-derived compounds rather than single purified active ingredients. In response, manufacturers are investing in improved purification processes—including advanced chromatography, membrane filtration, and lyophilization—to reduce immunogenic impurities. A user case from January 2026: Sinopharm Group Yibin Pharmaceutical announced a technology upgrade project (disclosed in the parent company’s annual securities filing) investing approximately USD 3.2 million in a new purification line for TCM injections, expected to reduce impurity-related adverse events by an estimated 40%.
Market Outlook and Strategic Implications (2025-2031)
Looking forward, the Potassium Dehydroandrographolide Succinate Injection market is projected to maintain its 5.6% CAGR, reaching USD 46.5 million by 2031. Growth will be supported by continued demand for TCM-based respiratory infection therapies in China’s integrated healthcare system, particularly during seasonal URTI outbreaks and as an alternative when antibiotic resistance limits conventional treatment options. However, growth will be moderated by regulatory pressures toward higher quality standards, competition from conventional antiviral and anti-inflammatory agents, and limited international market expansion opportunities. For pharmaceutical company executives, key strategic priorities include investing in purification technologies to meet evolving NMPA standards, conducting post-marketing safety studies to generate reliable adverse event data, and exploring evidence-based clinical research to validate efficacy for specific indications. For hospital pharmacy directors, the key considerations include evaluating the risk-benefit profile of TCM injectables relative to conventional alternatives, monitoring local adverse event data, and managing formulary placement within respiratory infection treatment algorithms. The complete QYResearch report includes detailed volume-based forecasts by dosage strength, regional consumption analysis across Chinese provinces, and competitive benchmarking of the 14 leading manufacturers, along with analysis of NMPA regulatory trends and their impact on market consolidation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
